Anthropic reports early drug development results from Claude partnerships
Anthropic says its life sciences team has spent several months in research partnerships with six drug developers, including Bristol Myers Squibb, Generate Biomedicines and Enveda. Generate reports that a CAR T-cell design proposed with Claude Code was about 70% shorter than the standard version and worked better in lab tests. Enveda says Claude caught all 11 manufacturing documentation issues that human reviewers found, flagged seven more, and cut review time by 89%. Anthropic says the work is still mostly preclinical, and it expects a drug from its own muscular dystrophy program could be ready for human trials as soon as late 2028.